Literature DB >> 12456199

Developing the revised NICE appraisal technical guidance to manufacturers and sponsors: opportunity or threat?

Rod S Taylor1, John Hutton, Anthony J Culyer.   

Abstract

One of the principal roles of the National Institute for Clinical Excellence (NICE) is to appraise selected existing and emerging healthcare technologies and, as a result, produce guidance for the National Health Service (NHS) in England and Wales. A central part of this appraisal is the potential for manufacturers and sponsors to make a data submission. This paper describes the process of development of the second edition of technical guidance to manufacturers and sponsors for submission to NICE. The revision process took place during the period May 2000 and January 2001 and involved a number of key steps -- establishment of a guidance steering committee, review of current international guidelines of clinical and cost effectiveness, drafting of the guidance, detailed consultation with stakeholders, revision of the guidance and, finally, publication. The lessons learnt from revision of the NICE guidance for manufacturers and sponsors and some main issues for its future development are discussed.

Mesh:

Year:  2002        PMID: 12456199     DOI: 10.2165/00019053-200220150-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  6 in total

1.  Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme.

Authors:  S R Hill; A S Mitchell; D A Henry
Journal:  JAMA       Date:  2000-04-26       Impact factor: 56.272

Review 2.  Health economic guidelines--similarities, differences and some implications.

Authors:  J Hjelmgren; F Berggren; F Andersson
Journal:  Value Health       Date:  2001 May-Jun       Impact factor: 5.725

3.  Pharmaceutical regulation: the early experience of the NHS National Institute for Clinical Excellence (NICE) appraisal process--where are we headed?

Authors:  R Taylor
Journal:  Value Health       Date:  2001 Jan-Feb       Impact factor: 5.725

4.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.

Authors:  G W Torrance; D Blaker; A Detsky; W Kennedy; F Schubert; D Menon; P Tugwell; R Konchak; E Hubbard; T Firestone
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

5.  Use of economic evaluation guidelines: 2 years' experience in Canada.

Authors:  J F Baladi; D Menon; N Otten
Journal:  Health Econ       Date:  1998-05       Impact factor: 3.046

6.  Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Authors:  M F Drummond; T O Jefferson
Journal:  BMJ       Date:  1996-08-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.